Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Semaglutide for glucose intolerance in women with prior gestational diabetes
2022-502082-22-00Phase 4Authorised
- Sponsor
- UZ Leuven
- Start
- May 2023
- Modality
- Recombinant Proteins and Enzymes, Peptides
- Countries
- 1
01
Overview
Phase 4, randomised, double-blind trial in prediabetes and type 2 diabetes mellitus (T2DM) comparing Ozempic with Placebo (2 arms). Primary endpoint: Development of type 2 diabetes mellitus by 160 weeks. Planned start May 2023; status: authorised.
02
Drugs
03
Conditions
prediabetestype 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on 2022-502082-22-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2022-502082-22-00.